ASCO 2026: Ascentage Pharma is currently in nine registration trials, four of which are global studies intended for FDA and EMA filings. The founder, Dajun Yang, discusses this work, and ASCO data
- May 31
- 1 min read
He describes how Ascentage, which is already commercializing two medicines in China, has been working on its global programs. Plus, an overview of ASCO data (3 oral presentations and 3 posters) on the BCR-ABL inhibitor olverembatinib, Bcl-2 inhibitor lisaftoclax, and MDM2-p53 inhibitor alrizomadlin (APG-115).
.png){kind=logo}